Prescription opioid abuse: A literature review of the clinical and economic burden in the United States

Population Health Management

Volumn 17, Issue 6, 2014, Pages 372-387

  Meyer, Roxanne ^a   Patel, Anisha M ^a   Rattana, Stacy K ^b   Quock, Tiffany P ^c   Mody, Samir H ^a  

^a Janssen Scientific Affairs   (United States)

^b SYNEOS HEALTH   (United States)

^c Department of Genetic and Molecular Toxicology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OPIATE; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

COMORBIDITY; DRUG ABUSE; DRUG FATALITY; DRUG OVERDOSE; ECONOMIC EVALUATION; EMERGENCY WARD; HEALTH CARE COST; HEALTH CARE UTILIZATION; HOSPITALIZATION; HUMAN; MEDICAID; MEDLINE; OUTPATIENT; PRESCRIPTION; REVIEW; SYSTEMATIC REVIEW; ADULT; COST OF ILLNESS; FEMALE; MALE; MORTALITY; OPIOID-RELATED DISORDERS; STATISTICS AND NUMERICAL DATA; UNITED STATES;

ADULT; ANALGESICS, OPIOID; COST OF ILLNESS; FEMALE; HEALTH CARE COSTS; HUMANS; MALE; OPIOID-RELATED DISORDERS; PRESCRIPTION DRUGS; UNITED STATES;

EID: 84918571594     PISSN: 19427891     EISSN: 19427905     Source Type: Journal    
DOI: 10.1089/pop.2013.0098     Document Type: Review

References (49)

1. Manchikanti L. Prescription drug abuse: what is being done to address this new drug epidemic? Testimony before the Subcommittee on Criminal Justice, Drug Policy and Human Resources. Pain Physician 2006;9:287-321.
2. Birnbaum HG, White AG, Schiller M, Waldman T, Cleveland JM, Roland CL. Societal costs of prescription opioid abuse, dependence, and misuse in the United States. Pain Med 2011;12:657-667.
3. The National Survey on Drug Use and Health (NSDUH). 2010 NSDUH Table 1.18A-Nonmedical use of pain relievers in lifetime, past year, and past month, by detailed age category: numbers in thousands, 2009 and 2010. < http://www.samhsa.gov/data/NSDUH/2k10ResultsTables/NSDUH Tables2010R/HTM/Sect1peTabs1to46.htm#Tab1.18A >. Accessed January 31, 2013.
4. Substance Abuse and Mental Health Services Administration Office of Applied Studies. Treatment episode data set (TEDS): 1997-2007. National Admissions to Substance Abuse Treatment Services, DASIS Series: S-47. Rockville, MD: Department of Health and Human Services, 2009.
5. Batten HL, Horgan CM, Protas JM, et al. Drug services research survey. Phase II final report. Waltham, MA: Submitted to the National Institute on Drug Abuse. Institute for Health Policy. Brandeis University, February 12, 1993.
6. Bohnert AS, Valenstein M, Bair MJ, et al. Association between opioid prescribing patterns and opioid overdoserelated deaths. JAMA 2011;305:1315-1321.
7. The National Center for Health Statistics. NCHS data on drug poisoning deaths. December 2012. < http://www.cdc.gov/nchs/data/factsheets/factsheet-drug-poisoning.pdf >. Accessed August 21, 2013.
8. Rice DP, Kelman S, Miller LS. Estimates of economic costs of alcohol and drug abuse and mental illness, 1985 and 1988. Public Health Rep 1991;106:280-292.
9. Birnbaum HG, White AG, Reynolds JL, et al. Estimated costs of prescription opioid analgesic abuse in the United States in 2001: a societal perspective. Clin J Pain 2006;22: 667-676.
10. Center for Disease Control and Prevention (CDC). Vital signs: overdoses of prescription opioid pain relievers-United States, 1999-2008. MMWR Morb Mortal Wkly Rep 2011;60:1487-1492.
11. Volkow ND, McLellan TA, Cotto JH, Karithanom M, Weiss SR. Characteristics of opioid prescriptions in 2009. JAMA 2011;305:1299-1301.
12. Paulozzi LJ, Logan JE, Hall AJ, McKinstry E, Kaplan JA, Crosby AE. A comparison of drug overdose deaths involving methadone and other opioid analgesics in West Virginia. Addiction 2009;104:1541-1548.
13. Weisner CM, Campbell CI, Ray GT, et al. Trends in prescribed opioid therapy for non-cancer pain for individuals with prior substance use disorders. Pain 2009;145:287-293.
14. Hall AJ, Logan JE, Toblin RL, et al. Patterns of abuse among unintentional pharmaceutical overdose fatalities. JAMA 2008;300:2613-2620.
15. Paulozzi LJ, Budnitz DS, Xi Y. Increasing deaths from opioid analgesics in the United States. Pharmacoepidemiol Drug Saf 2006;15:618-627.
16. Franklin GM, Mai J, Wickizer T, Turner JA, Fulton-Kehoe D, Grant L. Opioid dosing trends and mortality in Washington State workers' compensation, 1996-2002. Am J Ind Med 2005;48:91-99.
17. Hansen RN, Oster G, Edelsberg J, Woody GE, Sullivan SD. Economic costs of nonmedical use of prescription opioids. Clin J Pain 2011;27:194-202.
18. Braden JB, Russo J, Fan MY, et al. Emergency department visits among recipients of chronic opioid therapy. Arch Intern Med 2010;170:1425-1432.
19. Substance Abuse and Mental Health Services Administration Office of Applied Studies. The DAWN report: trends in emergency department visits involving nonmedical use of narcotic pain relievers. Rockville, MD: Substance Abuse and Mental Health Services Administration Office of Applied Studies, 2010.
20. Paulozzi L, Baldwin G, Franklin G, et al. CDC grand rounds: prescription drug overdoses-a U.S. epidemic. MMWR Morb Mortal Wkly Rep 2012;61(1):10-13.
21. White AG, Birnbaum HG, Schiller MA, Waldman T, Cleveland JM, Roland CM. Economic impact of opioid abuse, dependence, and misuse. Am J Pharm Benefits 2011; 3(4):e59-e70.
22. Baldasare A. The cost of prescription drug abuse: a literature review. < http://www.docstoc.com/docs/98740436/20110106-cost-of-prescription-drug-abuse >. Accessed March 4, 2014.
23. Buse D, Manack A, Serrano D, et al. Headache impact of chronic and episodic migraine: results from the American Migraine Prevalence and Prevention study. Headache 2011; 52(1):3-17.
24. McAdam-Marx C, Roland CL, Cleveland J, Oderda GM. Costs of opioid abuse and misuse determined from a Medicaid database. J Pain Palliat Care Pharmacother 2010; 24(1):5-18.
25. Braker LS, Reese AE, Card RO, Van Howe RS. Screening for potential prescription opioid misuse in a Michigan Medicaid population. Fam Med 2009;41:729-734.
26. Cicero TJ, Wong G, Tian Y, Lynskey M, Todorov A, Isenberg K. Co-morbidity and utilization of medical services by pain patients receiving opioid medications: data from an insurance claims database. Pain 2009;144(1-2):20-27.
27. US Government Accountability Office (GAO). Medicaid: fraud and abuse related to controlled substances identified in selected states. < http://www.gao.gov/products/GAO-09-1004T >. Accessed March 4, 2014.
28. White AG, Birnbaum HG, Mareva MN, et al. Direct costs of opioid abuse in an insured population in the United States. J Manag Care Pharm 2005;11:469-479.
29. Barnett PG. Comparison of costs and utilization among buprenorphine and methadone patients. Addiction 2009; 104:982-992.
30. Ettner SL, Huang D, Evans E, et al. Benefit-cost in the California treatment outcome project: does substance abuse treatment "pay for itself"? Health Serv Res 2006;41(1): 192-213.
31. Buse DC, Pearlman SH, Reed ML, Serrano D, Ng-Mak DS, Lipton RB. Opioid use and dependence among persons with migraine: results of the AMPP study. Headache 2012; 52(1):18-36.
32. Daubresse M, Chang HY, Yu Y, et al. Ambulatory diagnosis and treatment of nonmalignant pain in the United States, 2000-2010. Med Care 2013;51:870.
33. Manchikanti L, STAATS PS, Singh V, et al. Evidencebased practice guidelines for interventional techniques in the management of chronic spinal pain. Pain Physician 2003;6:3-80.
34. Gureje O, Von Korf M, Simon GE, Gater R. Persistent pain and well-being: a World Health Organization study in primary care. JAMA 1998;280:147-151.
35. Bressler HB, Keyes WJ, Rochon PA, Badley E. The prevalence of low back pain in the elderly. A systemic review of the literature. Spine 1999;24:1813-1819.
36. United States Department of Justice, Drug Enforcement Administration, Office of Diversion Control. Practitioner's manual: an informational outline of the Controlled Substances Act of 1970. < http://www.deadiversion.usdoj.gov/pubs/manuals/pract/index.html >. Accessed March 4, 2014.
37. Commonwealth of Kentucky, Cabinet for Health and Family Services, Office of the Inspector General. Kentucky All Schedule Prescription Electronic Reporting (KASPER). A comprehensive report on Kentucky's prescription monitoring program. < http://chfs.ky.gov/nr/rdonlyres/7057e43de1fd-4552-a902-2793f9b226fc/0/kaspersummaryreportversion2.pdf>. Accessed March 4, 2013.
38. Drug Strategies. Internet Drugs: Testimony before the US House of Representatives. Statement of Barbara Van Rooyan, July 6, 2006. < http://www.drugstrategies.com/int-rooyan.html >. Accessed March 4, 2014.
39. US Government Accountability Office. Prescription drugs: state monitoring programs provide useful tool to reduce diversion. < http://www.gao.gov/products/GAO-02-634 >. Accessed March 4, 2014.
40. United Nations Office on Drugs and Crime (UNODC). World drug report 2005. < http://www.unodc.org/unodc/en/dataand-analysis/WDR-2005.html >. Accessed January 31, 2013.
41. Trescot AM, Boswell MV, Atluri SL, et al. Opioid guidelines in the management of chronic non-cancer pain. Pain Physician 2006;9:1-40.
42. Lawrence RC, Helmick CG, Arnett FC, et al. Estimates of the prevalence of arthritis and selected musculoskeletal disorders in the United States. Arthritis Rheum 1998;41:778-799.
43. Drug Strategies. Internet Drugs: Testimony before the US House of Representatives. Statement of Mathea Falco President, Drug Strategies, July 26, 2006. < http://www.drug strategies.com/int-falco.html >. Accessed March 4, 2014.
44. Catan T, Perez E. A pain-drug champion has second thoughts. < http://online.wsj.com/news/articles/SB10001 424127887324478304578173342657044604 >. Accessed March 4, 2014.
45. Tudor CG; Department of Health and Human Services, Centers for Medicare and Medicaid Services. Memo to all Part D sponsors: Medicare Part D overutilization monitoring system. < http://www.amcp.org/uploadedFiles/Production- Menu/Policy-Issues-and-Advocacy/Letters,-Statements- and-Analysis-docs/2013/OMS%20HPMS%20Announcement% 20Memo-FINAL-070513.pdf >. Accessed March 4, 2014.
46. Foreman J. Backlash against Walgreen's new painkiller crackdown. < http://commonhealth.wbur.org/2013/08/walgreens-painkiller-crackdown >. Accessed January 17, 2013.
47. Substance Abuse and Mental Health Services Administration Office of Applied Studies. National survey of substance abuse treatment services (NSSATS): 2002. < http://www.samhsa.gov/data/DASIS/02nssats/nssats2002report.pdf >. Accessed March 4, 2014.
48. US Department of Health and Human Services, Substance Abuse and Mental Health Services, Office of Applied Studies. Results from the 2003 national survey on drug use and health: national findings. < http://www.samhsa.gov/data/nhsda/2k3nsduh/2k3ResultsW.pdf >. Accessed March 4, 2014.
49. Substance Abuse and Mental Health Services Administration. Strategies and interventions for reducing nonmedical use of prescription drugs: a review of literature (2006-2013). < http://captus.samhsa.gov/access-resources/strategies-andinterventions-reducing-nonmedical-use-prescription-drugsreview-lite >. Accessed November 20, 2013.